Placeholder Banner

BIO FILES AMICUS BRIEF CHALLENGING FTC’S OVERREACH ON MERGER ENFORCEMENT THAT THREATENS DRUG DEVELOPMENT INNOVATION

August 24, 2023
Media Contact
JG
2027471281

BIO released the following statement from John Delacourt, BIO’s Deputy General Counsel, on BIO’s amicus brief opposing the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen:

“The FTC’s current overreach in antitrust merger enforcement is of great concern to BIO and its members. Recent actions indicate a shift away from 40 years of FTC decisions that supported an ecosystem delivering life-saving treatments to patients. We filed this amicus brief to challenge the FTC’s sudden focus on restricting mergers and acquisitions in the biotech industry, creating an environment that chills investment for new, cutting-edge therapies. It is throwing a boulder on the tracks of a speeding train, disrupting a longstanding business model that depends on acquisitions to drive innovation.”

Related Resources
BIO FILES AMICUS BRIEF CHALLENGING FTC’S OVERREACH
Discover More
New Season of I am BIO Podcast to Showcase  Life-Changing Biotech Breakthroughs Launching February 27, spring 2024 season explores a new CRISPR therapy, advances in microbiome research, biotech for pets and more  WASHINGTON – (Feb. 23,…
The Creating Hope Reauthorization Act of 2024 was introduced in the House of Representatives this week. BIO CEO and President, Rachel King, made the following statement following the bill's introduction: "BIO strongly supports the House…
Legislation to restore immediate R&D expensing passed the House by 357-70 yesterday. Following the vote, BIO's Chief Advocacy Officer, Nick Shipley, made the following statement:  "The bipartisan legislation passed by the U.S. House…